Single-Dose Contrast Agent for Intraoperative MR Imaging of Intrinsic Brain Tumors by Using Ferumoxtran-10

Matthew A. Hunt, Attila G. Bagó, and Edward A. Neuwelt

BACKGROUND AND PURPOSE: Intraoperative MR imaging (IMRI) has advantages over conventional framed and frameless techniques. IMRI, however, also has some drawbacks, especially related to interpretation of gadolinium-enhanced intraoperative imaging resulting from surgically induced blood brain barrier injury, vascular changes, and hemorrhage. Ultra-small superparamagnetic iron particles like ferumoxtran-10 have a long plasma half-life and are trapped by reactive cells within the tumor. These trapped particles provide a method to demonstrate enhancing lesions without the artifact of repeat gadolinium administration in the face of blood brain barrier and vascular injury.

METHODS: We present a review of the literature and the cases of two patients who underwent surgery in which IMRI with ferumoxtran-10 was used.

RESULTS: Ultra-small superparamagnetic iron particles represent a method to demonstrate enhancing intrinsic brain tumors without the drawbacks of intraoperative gadolinium enhancement. These lesions appear even on low-field strength IMRI. Ferumoxtran-10, administered preoperatively, provides a stable imaging marker, even after surgical manipulation of the brain.

CONCLUSION: Ferumoxtran-10 provides a way to lessen artifactual enhancement during IMRI related to the administration of gadolinium.

Intraoperative MR imaging (IMRI) provides a unique opportunity for an early look at surgical biopsy and resection results. No other technique currently has the ability to evaluate the location and margins of a biopsy or resection and guide both the approach and further intervention during a single operative setting. Ferumoxtran-10 is an ultra-small superparamagnetic iron oxide (USPIO) particle that can delineate intracranial tumors with peritumoral reactive changes (1, 2). Intraoperative enhancement with gadolinium may reduce the accuracy of IMRI by making surgically disrupted areas of blood brain barrier enhance on the intraoperative images (3–7).

We present two patients who underwent preoperative MR imaging with gadolinium and then with ferumoxtran-10 and then underwent resection for an intrinsic brain tumor with IMRI. These patients demonstrate, along with previously published reports, the efficacy of IMRI without the potential pitfalls of recurrent gadolinium administration, especially in the operative environment (3, 4). In addition, USPIO particles, despite their large size when compared with traditional contrast agents, may provide better imaging of the entire tumor burden, both where the blood brain barrier is grossly and minimally defective. Unlike other contrast agents, ferumoxtran-10 has a 1–2-day plasma half-life and can be histologically identified in the tumor specimen due to CNS cellular trapping (8). IMRI may improve the ability to resect intrinsic brain tumors and even patient outcomes (9, 10).

Methods

Two patients were enrolled into an institutional review board approved study of ferumoxtran-10 (Combidx, Advanced Magnetics, Cambridge, MA). Both patients had a prior diagnosis of an intrinsic brain tumor: one anaplastic oligodendroglioma and one glioblastoma. The patients underwent MR imaging, including T1-weighted (TE 9, TR 400), proton density-weighted (9.3, 2000), T2-weighted (90, 4500), fluid attenuated inversion recovery (FLAIR; 130, 8800), and postgadolinium T1-weighted sequences. They then received a dose of ferumoxtran-10 (2.6 mg Fe/kg, diluted in 50 mL of normal saline at 4 mL/min). Twenty-four hours later, on the morning of surgery, each patient underwent another MR imaging, including T1-weighted, T2-weighted, gradient echo (23, 750), and diffusion-weighted (90, 10 000) sequences. The patients were then taken to the operating room for resection of their lesion guided by a Polestar N-10 0.15T IMRI unit (Odin Medical Technologies, Yokneam Elit, Israel), which allows both imaging and frameless stereotactic guidance from the intraoperative environment.

Received June 11, 2004; accepted after revision September 8.

From the Departments of Neurosurgery (M.A.H., E.A.N.) and Neurology (A.G.B., E.A.N.), Oregon Health and Science University, Portland, OR.

Address correspondence to Edward A. Neuwerk, MD, 3181 SW Sam Jackson Park Road, Mailcode L603, Portland, OR 97239.

© American Society of Neuroradiology
images. Intraoperative images were obtained by using T1-weighted sequences (2.9, 80). Both patients then underwent postoperative MR imaging, including T1-weighted, T2-weighted, proton density-weighted, gradient echo, diffusion-weighted, and postgadolinium T1-weighted sequences, within 72 hours of the operation to assess residual iron enhancement.

**Patient 1**

Patient 1 is a 41-year-old man with a history of anaplastic oligodendroglioma last resected in April 2000. The patient then underwent chemotherapy with procarbazine, carmustine, and vincristine. Repeat MR imaging showed a stable tumor until Fall 2002. Then he was enrolled in the ferumoxtran-10 study and underwent MR imaging as described above. Twenty-four hours later, the patient went to the operating room for resection of his recurrent tumor by using IMRI. Pathologic examination of the tumor revealed recurrent anaplastic oligodendroglioma.

**Patient 2**

Patient 2 is a 66-year-old man with a diagnosis of glioblastoma multiforme who had undergone prior resection at another institution in October 2002. The patient was referred to our institution for further care in November 2002. En route to our hospital, the patient had a decrease in his level of consciousness and was treated in another hospital with an increased dose of dexamethasone. On arrival to our hospital, the patient was admitted, underwent repeat MR imaging, and was then enrolled in the ferumoxtran-10 study and underwent MR imaging as described above. Twenty-four hours later, the patient went to the operating room for resection of his recurrent tumor by using IMRI. Pathologic examination of the tumor revealed recurrent anaplastic oligodendroglioma.

**Results**

Both patients underwent IMRI-guided resection of their tumors. Preoperative MR imaging demonstrated the targeted lesion. Intraoperative MR without gadolinium, following the prior administration of ferumoxtran-10, easily provided images that demonstrated the lesions seen on preoperative MR images obtained in both patient 1 (Fig 1) and patient 2 (Fig 2). In one operation, post-resection imaging revealed a persistently enhancing area that was then resected (Fig 3). Even in the low-field-strength IMRI system, ferumoxtran-10 provided adequate imaging of the lesions in both of these patients. Postoperative MR images obtained in both patients had no significant enhancement with gadolinium, which suggests resection of the enhancing tumor bulk (Figs 4 and 5). Both postoperative MRIs show high T1 signal intensity in the wall of the resection cavity. The walls of the cavities, however, do not appear to enhance significantly with gadolinium. Figure 5 also shows the resection cavity itself filled with T1 hyperintense material. The cause of this residual T1 hyperintensity, either from blood or ferumoxtran, is unclear. Iron staining of one patient’s lesion demonstrated iron accumulation within peritumoral reactive cells (Fig 6).

**Discussion**

Intraoperative MR imaging provides the most up-to-date data on tumor location, showing any movement of the tissue, the amount of tumor resected, and any residual tumor. Traditional image guidance systems, based on preoperative scanning, do not provide any data about intraoperative brain shift and cannot evaluate for any residual tumor. IMRI updates guidance systems and provides the most current location of intracranial lesions to best guide the surgeon in performing the most complete resection possible (10–13). IMRI does have limitations of limited avail-
ability and need for special operating room equipment, increased operating room time, and in some cases a smaller imaging field.

To visualize most tumors, administration of gadolinium has generally been necessary (3, 14–18). This practice may have pitfalls related to surgically induced enhancement of the operative site due to vascular leak, luxury perfusion, and other changes (3, 4, 6, 7, 19–23). Double-dose administration of gadolinium needed for good visualization of the tumor in low-field-strength IMRI environments may worsen the problem (24). If more than one intraoperative assessment of the resection is needed, gadolinium may also need to be dosed more than once. In addition, blood and hemostatic agents can also affect the appearance of MR imaging (25–27). IMRI provides the ability to confirm visually a bloodless operative field before and after imaging and confirm tumor resection without the confounding effects of postoperative brain enhancement (28).

The use of USPIO particles has been suggested as a partial remedy for this problem (8, 29). The USPIO particles have T1 and T2 shortening effects that provide the basis for their use as a contrast agent (1, 2, 8). These particles have a much longer plasma half-life than gadolinium, which provides them an opportunity to cross the blood brain barrier long after gadolinium has been excreted. Over time, the USPIO particles are taken up and trapped by reactive cells, such as microglia, macrophages, and astrocytes, in the brain parenchyma, which causes persistent enhancement without the need for further contrast medium administration. Although ferumoxtran-10 is not trapped by the tumor cells, it does localize to the same area as the tumor. To date, in 62 patients who have received ferumoxtran and 22 patients who went on to image-guided surgery, iron staining was not found in any area that did not have tumor histologically. In no case was normal brain resected at the lesion margins (authors’ unpublished data). To our knowledge, there is currently no clinically applicable way to confirm the presence of gadolinium in a pathologic specimen. This fixation of the contrast agent within reactive cells in the brain parenchyma, as visualized with histochsistry, reduces the hazards of relying on the flux of a contrast agent back and forth across an incompetent blood brain barrier. It may also demonstrate areas where tumor has caused more subtle disruptions in the blood brain barrier (1).

With a half-life of 24–30 hours for ferumoxtran-10, the question whether this agent could also cause enhancement of surgically traumatized tissues is valid, if surgery occurs between 24–48 hours after administration of the ferumoxtran-10. There is no evidence that enough ferumoxtran-10 accumulates within the interstitial spaces of the brain during the time span of surgery to alter significantly the appearance of MR imaging in surgically traumatized brain (1, 8, 30–32). One animal study demonstrated no increased postoperative signal intensity from USPIO particles given 16 hours preoperatively but did show intense gadolinium enhancement in the surgically disturbed brain (29).

The ability to perform more accurate resection of a brain tumor is the driving force behind IMRI. In early testing, ferumoxtran-10 may provide a way to avoid
problems with postsurgical, nontumoral enhancement in the intraoperative setting. This timing allows the evaluation of the tumor resection before hemostatic agents have been placed that may confound attempts to interpret postoperative MR imaging (25). More experience is needed with the use of ferumoxtran-10 and IMRI, but this agent may provide a means to better delineate brain tumors in the intraoperative settings. Even in limited-field-strength magnets used in many IMRI systems, ferumoxtran-10 provides a
stable imaging marker that can be confirmed pathologically.

Conclusion
Ferumoxtran-10 provides a solution to the problems related to gadolinium administration during IMRI. Our preliminary data suggest that ferumoxtran-10 provides a stable imaging marker that can be given once preoperatively and provide adequate images for IMRI-guided surgery.

Acknowledgments
Financial support for this work was provided by a Veteran’s Administration merit review grant and by grants NS44687, NS33618 and NS34608 from the National Institute of Neurologic Disorders and Stroke (to E.A.N.). Combidex (IRB NS33618 and NS34608 from the National Institute of Neurologic Disorders and Stroke (to E.A.N.). Combidex (IRB NS33618 and NS34608 from the National Institute of Neurologic Disorders and Stroke (to E.A.N.). Combidex (IRB NS33618 and NS34608 from the National Institute of Neurologic Disorders and Stroke (to E.A.N.). Combidex (IRB NS33618 and NS34608 from the National Institute of Neurologic Disorders and Stroke (to E.A.N.). Combidex (IRB NS33618 and NS34608 from the National Institute of Neurologic Disorders and Stroke (to E.A.N.).

References